, /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is pleased to announce that Sharon Mates, PhD, and Steven Paul, MD, have been named the recipients of the ISCDD Leadership Award at its 23rd Annual Meeting.

The awards were presented by Dr. Amir Kalali, and Dr. Bill Martin on behalf of the ISCDD leadership.

Dr. Kalali remarked: "Dr. Sharon Mates combines a unique background in neuropsychopharmacology, business, and leadership skills that have shepherded new treatments for patients. It is our honor to acknowledge Sharon's impact on CNS drug development over many decades."

"Dr. Steven Paul has been singularly successful in developing multiple new breakthrough treatments for patients. It is our honor to acknowledge his impact in CNS drug development over many decades."

Dr. Martin, Chairman of the ISCDD Executive Committee, added: "Dr. Sharon Mates' visionary leadership and commitment to innovation have helped transform the CNS drug development landscape. Her deep scientific expertise, relentless curiosity, and patient-centered approach have led to transformational innovations that continue to make a meaningful difference in the lives of so many patients."

"Dr. Steve Paul is the quintessential physician-scientist – a true visionary who has transformed the theoretical understanding of complex neurological disorders into tangible therapeutic breakthroughs that have helped restore function and dignity for millions of patients."

Dr. Mates said: "I am deeply honored to accept the International Society for CNS Drug Development Leadership Award. I share this achievement with the ITCI scientists, researchers, and healthcare professionals who work tirelessly to find innovative therapies for some of the most complex and challenging CNS disorders. I am inspired every day by their commitment to advancing our understanding of the brain. We are proud of the hundreds of thousands of patients we have helped."

Dr. Paul said: "I am deeply honored to receive this award from the ISCDD, a group of dedicated and experienced CNS drug developers who fully appreciate the challenges and opportunities of developing new medicines for some of the most disabling and potentially fatal brain disorders. Many members of ISCDD were instrumental in the successful development of the CNS medicines I have been passionate about and have worked on for years, so my gratitude extends well beyond receiving this award—and is really on behalf of the millions of patients and their families who benefit from our collaborative work."

Founded in 2002, the ISCDD is a non-profit, independent leadership forum that brings together academia, industry, and government stakeholders to foster collaboration and drive progress in CNS drug development.

For more information, please contact:

ISCDD Secretariat
Phone: 702-992-0784
Email: [email protected] 
LinkedIn: linkedin.com/company/cns-summit/

SOURCE International Society for CNS Drug Development

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3

440k+
Newsrooms &
Influencers

icon1

9k+
Digital Media
Outlets

icon2

270k+
Journalists
Opted In